About: Methotrexate update 2014: 70 years in autoimmunity and cancer treatment

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Methotrexate update 2014: 70 years in autoimmunity and cancer treatment Goto Sponge NotDistinct Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

Attributes	Values
rdf:type	skos:Concept http://linked.opendata.cz/ontology/domain/vavai/Vysledek
rdfs:seeAlso	http://www.prolekare.cz/cesko-slovenska-pediatrie-clanek/70-let-methotrexatu-v-lecbe-autoimunitnich-a-nadorovych-onemocneni-49621
Description	Immunosupressive and antineoplastic activity brought methotrexate to its clinical use many years ago. Although modern antitumour and antiinflammatory drugs and new antifolates have challenged methotrexate, its use in rheumatoid arthritis and in some types of pediatric and adult malignancies remains a gold standard. The principal main mechanism of action of methotrexate is competitive inhibition of dihydrofolate reductase. Recently, other pharmacodynamic effects have been described. Potent inflammation inducers such as leukotriene-B4 and polyamine synthesis were found to be reduced by methotrexate treatment. Jun N-terminal kinase and B cell lymphoma 2 gene are downregulated by methotrexate. Its metabolite, 7-hydroxymethotrexate and also its intracellular polyglutamated forms show a different spectrum of inhibitory activity as well as potency towards dihydrofolate reductase and other enzymes. In this review, we summarize recent information data on methotrexate in both fields of its use, oncology and rheumatology. We also discuss new biomarkers of toxicity for further improvement of therapeutic protocols. Immunosupressive and antineoplastic activity brought methotrexate to its clinical use many years ago. Although modern antitumour and antiinflammatory drugs and new antifolates have challenged methotrexate, its use in rheumatoid arthritis and in some types of pediatric and adult malignancies remains a gold standard. The principal main mechanism of action of methotrexate is competitive inhibition of dihydrofolate reductase. Recently, other pharmacodynamic effects have been described. Potent inflammation inducers such as leukotriene-B4 and polyamine synthesis were found to be reduced by methotrexate treatment. Jun N-terminal kinase and B cell lymphoma 2 gene are downregulated by methotrexate. Its metabolite, 7-hydroxymethotrexate and also its intracellular polyglutamated forms show a different spectrum of inhibitory activity as well as potency towards dihydrofolate reductase and other enzymes. In this review, we summarize recent information data on methotrexate in both fields of its use, oncology and rheumatology. We also discuss new biomarkers of toxicity for further improvement of therapeutic protocols. (en)
Title	Methotrexate update 2014: 70 years in autoimmunity and cancer treatment Methotrexate update 2014: 70 years in autoimmunity and cancer treatment (en)
skos:prefLabel	Methotrexate update 2014: 70 years in autoimmunity and cancer treatment Methotrexate update 2014: 70 years in autoimmunity and cancer treatment (en)
skos:notation	RIV/00209805:_____/14:#0000563!RIV15-MSM-00209805
http://linked.open...avai/riv/aktivita	P
http://linked.open...avai/riv/aktivity	P(ED2.1.00/03.0101)
http://linked.open...iv/cisloPeriodika	3
http://linked.open...vai/riv/dodaniDat	2015
http://linked.open...aciTvurceVysledku	Dubská, Lenka Pilátová, Kateřina Řiháček, Michal
http://linked.open.../riv/druhVysledku	J - Článek v odborném periodiku
http://linked.open...iv/duvernostUdaju	S - Úplné a pravdivé údaje nepodléhající ochraně podle zvláštních právních předpisů
http://linked.open...titaPredkladatele	Masarykův onkologický ústav
http://linked.open...dnocenehoVysledku	28694
http://linked.open...ai/riv/idVysledku	RIV/00209805:_____/14:#0000563
http://linked.open...riv/jazykVysledku	eng - angličtina
http://linked.open.../riv/klicovaSlova	methotrexate; autoimmunity; neoplasms; biological markers; toxicity; adverse effects (en)
http://linked.open.../riv/klicoveSlovo	neoplasms autoimmunity toxicity biological markers methotrexate adverse effects
http://linked.open...odStatuVydavatele	CZ - Česká republika
http://linked.open...ontrolniKodProRIV	[744617DDBEF8]
http://linked.open...i/riv/nazevZdroje	Česko-Slovenská pediatrie
http://linked.open...in/vavai/riv/obor	FD
http://linked.open...ichTvurcuVysledku	3 (xsd:int)
http://linked.open...cetTvurcuVysledku	4 (xsd:int)
http://linked.open...vavai/riv/projekt	Regional Centre for Applied Molecular Oncology (RECAMO)
http://linked.open...UplatneniVysledku	2014
http://linked.open...v/svazekPeriodika	69
http://linked.open...iv/tvurceVysledku	Pilátová, Kateřina Zdražilová Dubská, Lenka Řiháček, Michal
issn	0069-2328
number of pages	7 (xsd:int)

Faceted Search & Find service v1.16.118 as of Jun 21 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software